Groupe d'Etude en Oncologie du Quebec

Title	Elranatamab post trial access: an open-label, single-arm study for participants with multiple myeloma continuing from Pfizer-sponsored Elranatamab clinical studies
Protocole ID	MagnetisMM15
ClinicalTrials.gov ID	NCT06057402
Cancer Type(s)	Myeloma
Phase	Other
Stage
Study Type	Clinical
Drug	Elranatamab
Institution	CENTRE UNIVERSITAIRE DE SANTE MCGILL SITE GLEN 1001 boul. Décarie , Montréal, QC, H4A 3J1
City
Principal Investigator	Dr. Chaim Shustik Dr. Michael Sebag
Coordinator	Nancy Renouf 514-934-1934 poste 35718
Status	Recruiting
Activation Date
Eligibility Criteria	Participants must agree to follow the reproductive criteria as outlined in the protocol Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).
Exclusion Criteria	Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.

Groupe d'étude en oncologie du Québec